Please assess the completion status of the following clinical trial:

Trial Title: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT):~* Willing and able to participate as a research subject and provide informed consent (Note: an LAR may sign the consent form on the partipant's behalf)~* Diagnosis of relapsed refractory multiple myeloma defined as more than 2 lines of prior therapy with at least a very good partial remission to most recent salvage therapy.~  * Patients should have R-ISS stage II or III disease at diagnosis or high risk cytogenetics by IMWG criteria (t(4;14), del(17/17p), t(14;16), t(14;20), nonhyperdiploidy, and gain(1q)) at any time since diagnosis~Note:. A line of therapy is treatment between diagnosis and progression or between two progressions~* Eligible for CD34-selected HSCT according to MSKCC adult BMT guidelines.~* Have a 10/10 matched donor~* Age ≥ 21, \< 73 years.~* Karnofsky (adult) Performance Status ≥ 70%.~* Patients must have adequate organ function measured by:~  1. Cardiac: LVEF at rest must be ≥ 50%~ 2. Hepatic:~     * \< 3x ULN ALT~    * \< 1.5 ULN total serum bilirubin, unless there is congenital benign hyperbilirubinemia.~ 3. Renal: serum creatinine \<1.2 mg/dl or if serum creatinine is outside the normal range, then CrCl \> 40 ml/min (measured or calculated/estimated) with dose adjustment of Fludarabine for \<70ml/min~ 4. Pulmonary: DLCO \> 50% of predicted (corrected for hemoglobin).~Inclusion Criteria prior to Ipilimumab:~* Non progressive myeloma (partial response or better) as defined by International Myeloma Working Group (IMWG) criteria~* Engraftment of all cell lines without transfusion dependence, defined as:~  * absolute neutrophil count \> 1.0K/mcL x 3 consecutive days~ * platelets \> 50K/mcLx 7 consecutive days without platelet transfusion~ * no platelet or RBC transfusions within the preceding 7 days~* ≥ 80% donor chimerism in the bone marrow~Exclusion Criteria:~Exclusion Criteria prior to Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT):~* Patients ineligible for therapy with ipilimumab, for example:.~  1. Active autoimmune disease or any condition requiring systemic treatment with either corticosteroids (\>10 mg daily of prednisone equivalents) or other immunosuppressive medications at enrollment. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.~ 2. History of motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre Syndrome, Myasthenia Gravis).~* Female patients who are pregnant or breast-feeding.~* Patients with plasma cell leukemia at the time of diagnosis.~* Patients who have undergone prior allogeneic hematopoietic stem cell transplantation.~* Patients who have had a previous malignancy that is not in remission.~Exclusion Criteria prior to Ipilimumab:~* Active infection or treatment for infection (patients on Cytomegalovirus (CMV) therapy will be considered eligible; patients with CMV viremia by PCR or disease with end-organ involvement will not be eligible)~* Active GVHD of any grade or prior grade 3-4 GVHD~* Active immune suppression, defined as:~  * active use of calcineurin inhibitors, mycophenolate mofetil, or other immunomodulators~ * steroid dosing exceeding 10 mg/d prednisone or equivalent~* Receiving immunomodulatory agents (ex. thalidomide, lenalidomide, pomalidomide)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 73 Years
- Healthy Volunteers: f

Study Arms:
- Ipilimumab After Stem Cell Transplantation (Type: EXPERIMENTAL): The patient will be admitted to a single room on the Adult Transplantation Service and allogeneic CD34-selected PBSC or marrow transplantation performed as per MSKCC adult BMT guidelines. Patients will be evaluated at approximately day 100 (±2 weeks) after allo-HSCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).